GlaxoSmithKline Pharmaceuticals Limited

NSE:GLAXO.NS

2561.15 (INR) • At close November 8, 2024
Overzicht | Financiële gegevens

Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) INR.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q1
Omzet 10,107.78,146.59,2988,052.69,569.97,616.67,874.58,0239,168.77,4518,096.2928,159.210,098.77,899.98,137.5228,5728,793.26,485.97,758.0077,785.98,820.27,879.77,508.0888,253.58,163.17,356.55,829
Kosten van de omzet 3,844.94,629.65,580.63,168.43,544.42,961.23,447.92,880.83,6512,8694,448.2393,201.64,031.13,101.24,186.2293,512.53,674.72,573.33,691.3453,277.53,698.73,307.93,915.8663,825.83,491.23,167.42,709.5
Brutowinst 6,262.83,516.93,717.44,884.26,025.54,655.44,426.65,142.25,517.74,5823,648.0534,957.66,067.64,798.73,951.2935,059.55,118.53,912.64,066.6624,508.45,121.54,571.83,592.2224,427.74,671.94,189.13,119.5
Brutowinstmarge 0.620.4320.40.6070.630.6110.5620.6410.6020.6150.4510.6080.6010.6070.4860.590.5820.6030.5240.5790.5810.580.4780.5360.5720.5690.535
Onderzoek- en ontwikkelingskosten 0025.43700019.09900018.285000000021.80200023.2660000
Algemene en administratieve kosten 00232.168000149.566000153.2200000001,789.4550001,811.190000
Verkoop- en marketingkosten 001,093.6320001,091.2340001,276.8800000001,382.2950001,203.640000
Verkoop-, algemene en administratieve kosten 1,538.61,375.61,325.81,290.11,678.51,566.61,240.81,325.31,5291,580.61,430.11,555.61,702.31,604.11,566.61,592.11,540.11,519.23,171.751,666.91,474.71,428.13,014.831,255.51,395.31,259.80
Overige kosten 3,214.3356.4-876.822281.1282.1364.42,9013,019.33,1123,2511,997.913,158.293.5105.2-319.522140.290.4152.4-631.899165158.8308.1-259.759165.8150.1177.8137.5
Bedrijfskosten 3,214.31,375.61,325.82,874.73,311.73,380.22,9013,019.33,1123,2511,997.913,158.23,478.43,459.12,072.343,092.23,289.52,989.63,509.4193,447.83,408.43,109.52,055.4163,176.63,136.72,8992,997.9
Bedrijfsresultaat 3,048.52,141.32,391.62,290.62,995.91,639.61,802.22,357.12,625.41,607.11,783.0391,902.62,589.21,339.61,878.9531,967.31,829923557.2431,060.61,713.11,462.31,536.8061,251.11,535.21,290.1121.6
Bedrijfsresultaat ratio 0.3020.2630.2570.2840.3130.2150.2290.2940.2860.2160.220.2330.2560.170.2310.230.2080.1420.0720.1360.1940.1860.2050.1520.1880.1750.021
Totaal overige inkomsten en kosten netto 389.6352.7314.6-1,636.3-4.3170.297.5-114.6-3.9-6.8295.442-185146.2309.4-1,248.87146.8-559.7568.41,208.288-7,403.84,161298.8681.887453.73093263
Inkomen voor belasting 3,438.12,4942,706.2654.32,991.61,809.81,899.72,242.52,621.51,600.32,078.4811,717.62,735.41,649630.0832,114.11,269.31,491.41,765.531-6,343.25,874.11,761.12,218.6931,704.81,565.21,383.1384.6
Inkomen voor belasting ratio 0.340.3060.2910.0810.3130.2380.2410.280.2860.2150.2570.2110.2710.2090.0770.2470.1440.230.228-0.8150.6660.2230.2960.2070.1920.1880.066
Belastingkosten 913.1670.7761.4197.1816.5487.3565.4596.9687.34382,625.092334.8693438.2486.81549504.6383.1384.785268.4846.6625.7750.563568.1556.9497.2120.4
Nettowinst 2,5251,823.31,944.81457.22,175.11,322.51,334.2681,645.61,934.21,192.8-546.6111,503.52,042.41,210.8143.2731,565.1764.71,108.31,380.746-6,611.65,027.51,135.41,468.131,136.71,008.3840.8264.2
Nettowinstmarge 0.250.2240.2090.0570.2270.1740.1690.2050.2110.16-0.0680.1840.2020.1530.0180.1830.0870.1710.178-0.8490.570.1440.1960.1380.1240.1140.045
WPA (Winst Per Aandeel) 14.9110.7611.482.712.847.817.889.7111.427.04-3.238.1712.067.150.859.244.516.548.14-39.0329.686.78.666.715.954.961.56
Verwaterde WPA 14.9110.7611.482.712.847.817.889.7111.427.04-3.238.1712.067.150.859.244.516.548.14-39.0329.686.78.666.715.954.961.56
EBITDA 3,609.42,305.42,572.62,461.73,1771,803.21,9742,521.22,7891,765.31,936.4992,081.32,914.91,8342,353.5162,284.62,1391,719.9789.5781,408.92,098.91,9612,142.9131,537.31,800.41,581.5334.3
EBITDA ratio 0.3570.2830.2770.3060.3320.2370.2510.3140.3040.2370.2390.2550.2890.2320.2890.2670.2430.2650.1020.1810.2380.2490.2850.1860.2210.2150.057